Real-Time Imaging to Improve Lung Cancer Diagnosis : Comparing Confocal Laser Endomicroscopy (CLE) With Standard Biopsy for Quicker and Safer Detection of Non-Small Cell Lung Cancer

NCT07538947 · tracked via the Priya Life Science France tracker

Sponsor

Central Hospital, Nancy, France

Phase

Observational

Started

2026-04-03

Last updated

2026-04-20

Condition(s) studied

Non Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

bronchoscopic navigation with CLE

bronchoscopic navigation with CLE: bronchoscopic navigation with real-time imagine (Confocal Laser Endomicroscopy)

Study summary

The goal of this observational study is to evaluate whether confocal laser endomicroscopy (CLE) can improve the real-time diagnosis of non-small cell lung cancer (NSCLC) in patients undergoing bronchoscopic biopsy for suspected lung tumors. The main questions it aims to answer are:

* Can a high-specificity CLE-based score accurately identify NSCLC during endoscopic procedures?
* Can CLE imaging criteria improve biopsy yield and help differentiate histological subtypes (e.g., squamous cell carcinoma, adenocarcinoma, carcinoid tumors)?

Participants will:

* Undergo standard bronchoscopic navigation procedures with additional real-time imaging using CLE and biopsy
* Have CLE findings compared with standard histopathological analysis of biopsy samples

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient for whom endobronchial navigation-guided biopsy is indicated * Complete medical data (CLE images and histopathological results) Exclusion Criteria: * Persons referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code: * Individuals under 18 years of age * Adult persons subject to legal protection measures (guardianship, curatorship, or judicial protection) * Adult persons unable to express their consent * Persons deprived of liberty by judicial or administrative decision, and persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1

Primary outcome measure(s)

Diagnostic accuracy of the CLE-based score for non-small cell lung cancer (NSCLC) detection — During the endoscopic procedure and confirmed after biopsy analysis (up to 7 days)
Proportion of cases in which the CLE imaging score correctly identifies NSCLC, using standard histopathology from biopsy samples as the reference standard

Trial sites (1)

Facility	City	Region	Status
CHRU Nancy	Nancy	France	Recruiting

More Central Hospital, Nancy, France trials in France

Satisfaction of Hysterosalpingo-Foam Sonography Enrolling by invitation

Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma Starting soon

Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions Recruiting

Contribution of Contrast Enhanced Ultrasound for Diagnosis of Adnexal Torsion Recruiting

DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study Starting soon

Other trials for the same condition

PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC Recruiting

Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy Active, not recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer Active, not recruiting

Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C Recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07538947 on ClinicalTrials.gov ↗ ← All trials in France